Atlas Venture
http://www.atlasventure.com/Atlas Venture is a venture capital firm that invests in early stage technology and life sciences businesses. Since the firm’s founding in 1980, the firm has helped build over three hundred companies. Since 1995, forty seven of its investments have been acquired and more than forty have gone public, with an aggregate market capitalization of over $20 billion.
View Older Stories View More Recent Stories
-
Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture
-
Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO
-
Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer
-
Navitor Pharmaceuticals Appoints Thomas E. Hughes, Ph.D. as Chief Executive Officer
-
Generation Bio Appoints Charles Rowland to its Board of Directors
-
Form 13F-HR Atlas Venture Associates For: Jun 30
-
Life Science Executives and Investors Connect with Biotech Startups at BioPharm America™ Global Partnering Event this September
-
Form 4 Replimune Group, Inc. For: Jul 24 Filed by: Atlas Venture Associates X, LLC
-
Disarm Therapeutics Presents Data Demonstrating the Protective Effect of SARM1 Deletion on Axonal Degeneration
-
Form 3 Replimune Group, Inc. For: Jul 19 Filed by: Atlas Venture Fund X, L.P.
-
IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 Million Series A Financing to Develop NLRP3 Antagonists for Inflammatory Diseases
-
HotSpot Therapeutics Completes $45 Million Series A Financing to Advance New Approach to Allosteric Drug Discovery
-
Form 4 Translate Bio, Inc. For: Jul 02 Filed by: Atlas Venture Fund VIII, L.P.
-
Form 4 ZAFGEN, INC. For: Jun 29 Filed by: Atlas Venture Associates VII, L.P.
-
Form 3 Translate Bio, Inc. For: Jun 27 Filed by: Atlas Venture Associates VIII, L.P.
-
Form 4 Magenta Therapeutics, For: Jun 25 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
-
Form 4 AVROBIO, Inc. For: Jun 25 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
-
Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases
-
Form 3 Magenta Therapeutics, For: Jun 20 Filed by: Atlas Venture Fund X, L.P.
-
Form 3 AVROBIO, Inc. For: Jun 20 Filed by: Atlas Venture Fund X, L.P.
-
Generation Bio Appoints Jeff Jonas M.D. to its Board of Directors
-
Atlas Venture Announces Andrea Armstrong Joins as Chief Talent Officer
-
Harvard Business School Names 2018-2019 Blavatnik Fellows in Life Science Entrepreneurship
-
BioPharm America™ Once Again Offers Top Quality Opportunities for Networking with Global Life Science Executives This September
-
Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins
-
Navitor Pharmaceuticals to Present at UBS Global Healthcare Conference
-
Plastiq Secures $27 Million in New Funding Round to Accelerate Growth of Payments Platform for Small Business
-
Rodin Therapeutics Expands Leadership Team, Adding Extensive Experience in Clinical and Business Development
-
Form 4 Carbon Black, Inc. For: May 08 Filed by: ATLAS VENTURE ENTREPRENEURS FUND VI LP
-
Form 13F-HR Atlas Venture Associates For: Mar 31
-
Generation Bio Expands Leadership Team with Appointment of Sara Den Besten as Head of Human Resources
-
Science 2 Startup Symposium Convened Over 230 Academic Researchers, Venture Capitalists, Entrepreneurs, and Pharmaceutical Executives, Creating Connections that can Advance Scientific Innovation and E
-
Form 3 Carbon Black, Inc. For: May 03 Filed by: ATLAS VENTURE ENTREPRENEURS FUND VI LP
-
Obsidian to Present Data on Regulated Cytokine Programs at the Upcoming American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting
-
Form 4 Atlas Venture Associates For: Apr 23 Filed by: Surface Oncology, Inc.
-
Form 3 Atlas Venture Associates For: Apr 18 Filed by: Surface Oncology, Inc.
-
Obsidian Therapeutics Presents Preclinical Data from Regulated Cytokine Programs that Enable CAR-T Therapies with Controllable Functions
-
Atlas Venture, F-Prime Capital Partners and SV Health Investors to Host Symposium Featuring Therapeutics Startup Ideas From World’s Top Academic Research Institutions
-
Be The Match BioTherapies Strengthens Partnership with Magenta Therapeutics
-
Magenta Therapeutics Secures $52 Million in Series C Financing
-
Generation Bio Strengthens Leadership Team with Appointment of Will McCarthy as Chief Business Officer and Jennifer Elliott, Ph.D., J.D., as Head of Legal Affairs and Intellectual Property
-
Magenta Therapeutics Appoints Amy Ronneberg, President of Be The Match BioTherapies, to Board of Directors
-
Magenta Therapeutics Announces First Patient Transplanted with MGTA-456 in Phase 2 Study in Inherited Metabolic Disorders
-
Form 4 Atlas Venture Associates For: Apr 03 Filed by: Unum Therapeutics Inc.
-
Magenta Therapeutics Announces Departure of Chief Operating Officer Bastiano Sanna, Ph.D.
-
Form 3 Unum Therapeutics, Inc. For: Mar 28 Filed by: Atlas Venture Associates IX, L.P.
-
Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231
-
Obsidian Therapeutics to Present at Upcoming Investor Conferences
-
Obsidian to Present Data on its Destabilizing Domain Technology and Product Programs at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting
-
Form SC 13D Spero Therapeutics, Inc. Filed by: Atlas Venture Fund X, L.P.

